Clinical Trial Update: Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker

View source ↗

Summary

A clinical trial evaluating whether tumor-specific T-cell immunity can serve as a prognostic marker in bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Snippet

Sponsor: Technical University of Munich | Conditions: Bladder Cancer | Status: UNKNOWN